Abstract Number: 1842 • ACR Convergence 2025
Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Background/Purpose: Socioeconomic environmental factors are associated with SLE disease activity and early mortality and may contribute to disease progression in at-risk populations. Blood relatives (BRs)…Abstract Number: 1763 • ACR Convergence 2025
Spatial Organization and Function of Disease-Associated Macrophages in Lupus Nephritis: Insights from Cross-Species Analyses
Background/Purpose: Myeloid cells are linked to kidney injury in lupus nephritis (LN) but lack targeted therapies, underscoring the need to better understand myeloid biology in…Abstract Number: 1699 • ACR Convergence 2025
Protein-coding Somatic Genetic Variation in Lymphocytes in Systemic Lupus Erythematosus
Background/Purpose: The genetic and environmental factors underlying pathogenesis of systemic lupus erythematosus (SLE) are incompletely resolved. While inherited genetic variation has been extensively queried in…Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…Abstract Number: 1534 • ACR Convergence 2025
Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…Abstract Number: 1515 • ACR Convergence 2025
Machine Learning–Defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
Background/Purpose: To refine clinical subtypes of systemic lupus erythematosus (SLE) using unsupervised machine learning, and to elucidate the molecular basis of disease heterogeneity through integrated…Abstract Number: 1492 • ACR Convergence 2025
Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder that is nine times more prevalent in women. Patients with SLE are at an…Abstract Number: 1474 • ACR Convergence 2025
Rethinking Heart Risk Prediction for Lupus Patients
Background/Purpose: Patients with lupus erythematosus (LE) are at an increased risk of clinical events from atherosclerotic cardiovascular disease (ASCVD), yet the accuracy of risk estimation…Abstract Number: 1289 • ACR Convergence 2025
Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Background/Purpose: Pain is a common symptom in childhood-onset systemic lupus erythematosus (cSLE) which impacts health-related quality of life. Its relationship to disease measures over time…Abstract Number: 1189 • ACR Convergence 2025
Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
Background/Purpose: Ianalumab, a glycoengineered IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via dual mechanism: depletion of B…Abstract Number: 1018 • ACR Convergence 2025
Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
Background/Purpose: The differences in lupus-related mortality reported in population studies are partly explained by racial disparities and access to healthcare. However, population-based data from universal…Abstract Number: 0936 • ACR Convergence 2025
Ultrasound-Mediated Blood–Brain Barrier Permeabilization Enables Targeted Drug Delivery in a Murine Model of Neuropsychiatric SLE
Background/Purpose: Neuropsychiatric SLE (NPSLE) is a severe complication of SLE, characterized by CNS involvement leading to cognitive, behavioral, and neurological deficits. While monoclonal antibodies may…Abstract Number: 0666 • ACR Convergence 2025
Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with heterogeneous symptoms, complicating diagnosis and treatment. Historically, treatment included broad immunosuppressants, but real-world data…Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…Abstract Number: 0621 • ACR Convergence 2025
Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disease. Pleuropulmonary (PP) manifestations, including pleural effusion (PE), interstitial lung disease (ILD), pulmonary hypertension (PH), shrinking…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 181
- Next Page »